REPLIGEN CORP Deferred Tax Liabilities, Intangible Assets
REPLIGEN CORP (RGEN) had Deferred Tax Liabilities, Intangible Assets of $67.01 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets · last filed 2026-02-26
- 2025-12-31: Deferred Tax Liabilities, Intangible Assets $67.01M.
- 2024-12-31: Deferred Tax Liabilities, Intangible Assets $63.13M.
- 2023-12-31: Deferred Tax Liabilities, Intangible Assets $58.47M; Deferred Tax Liabilities, Intangible Assets as first filed $56.96M.
- 2022-12-31: Deferred Tax Liabilities, Intangible Assets $45.17M; Deferred Tax Liabilities, Intangible Assets as first filed $43.55M.
| Period end | Deferred Tax Liabilities, Intangible Assets | Deferred Tax Liabilities, Intangible Assets as first filed |
|---|---|---|
| 2025-12-31 | $67.01M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $63.13M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $58.47M 10-K · filed 2025-03-14 | $56.96M 10-K · filed 2024-02-22 |
| 2022-12-31 | $45.17M 10-K/A · filed 2024-11-18 | $43.55M 10-K · filed 2023-02-22 |
| 2021-12-31 | $43.23M 10-K · filed 2023-02-22 | |
| 2020-12-31 | $28.64M 10-K · filed 2022-02-17 | $27.15M 10-K · filed 2021-02-24 |
| 2019-12-31 | $24.61M 10-K · filed 2021-02-24 | $26.81M 10-K · filed 2020-02-26 |
| 2018-12-31 | $26.90M 10-K · filed 2020-02-26 | |
| 2017-12-31 | $32.36M 10-K · filed 2019-03-01 | |
| 2011-12-31 | $89.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |